Proactive Investors - Omega Therapeutics shares surged more than 100% after it was announced it is partnering with Danish healthcare company Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to develop novel treatment approaches for cardiometabolic diseases.
Novo Nordisk (NYSE:NVO) said that its collaboration with Omega will develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.
The company also announced it was collaborating with private firm Cellarity to develop a small molecule therapy in metabolic dysfunction-associated steatohepatitis (MASH).
“It is essential that we complement our internal research with external innovation and work with partners who are bringing forward cutting-edge technology,” Novo Nordisk (NYSE:NVO) chief scientific officer Marcus Schindler said in a statement.
"Both companies offer differentiated and novel approaches, including Omega’s expertise in controlled epigenomic modulation and Cellarity’s deep insights into applying human data and artificial intelligence to the development of new medicines.”
Omega CEO Mahesh Karande added: “By leveraging Novo Nordisk (NYSE:NVO)’s deep expertise in the space and our OMEGA platform, we have the opportunity to tap into the body’s natural processes that control metabolic activity and potentially develop an alternative, more durable approach to obesity management.”
Omega Therapeutics shares were up 102.9% at US$5.55 before Thursday’s opening bell.